Back to today’s briefing

Story perspectives

Eli Lilly Soars 16% on Breakthrough Weight-Loss Drug

4/17/2025

28 7

Summary

Story summary

Eli Lilly's stock skyrocketed by 16% following promising Phase 3 trial results for orforglipron, an oral weight-loss drug. Patients with Type 2 diabetes shed an average of 16 pounds and saw a 1.3% drop in blood sugar levels. With plans to pursue FDA approval for obesity by late 2025 and diabetes in 2026, the market could be transformed.

1 of 1

Story summary

Eli Lilly's stock skyrocketed by 16% following promising Phase 3 trial results for orforglipron, an oral weight-loss drug. Patients with Type 2 diabetes shed an average of 16 pounds and saw a 1.3% drop in blood sugar levels. With plans to pursue FDA approval for obesity by late 2025 and diabetes in 2026, the market could be transformed.